Synovial Sarcoma

Oncology
3
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
3100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Design Therapeutics
1 program
1
LV305Phase 3
US WorldMeds
US WorldMedsKY - Louisville
3 programs
1
1
afamitresgene autoleucelPhase 2Cell Therapy1 trial
Afamitresgene autoleucelPhase 1/2Cell Therapy1 trial
Non-conforming afamitresgene autoleucelN/ACell Therapy1 trial
Active Trials
NCT06617572Available
NCT05642455RecruitingEst. Jul 2038
NCT04044768Active Not RecruitingEst. Apr 2038

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
US WorldMedsafamitresgene autoleucel
US WorldMedsAfamitresgene autoleucel

Clinical Trials (3)

NCT04044768US WorldMedsafamitresgene autoleucel

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Start: Aug 2019Est. completion: Apr 2038
Phase 2Active Not Recruiting
NCT05642455US WorldMedsAfamitresgene autoleucel

SPEARHEAD-3 Pediatric Study

Start: Sep 2023Est. completion: Jul 2038
Phase 1/2Recruiting
NCT06617572US WorldMedsNon-conforming afamitresgene autoleucel

Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel

N/AAvailable

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials
Cell Therapy is the dominant modality (100% of programs)
2 companies competing in this space